News at Geistlich Pharma AG

  • Bone volume augmented with Geistlich Bio-Oss® remains stable over the long term. The reason for this appears to be the gradual absorption of the material, as shown in a recent study by the research group headed by Daniel Buser.
  • Today, Friday, Geistlich Pharma was to collect the 2014 IHZ (Chamber of Industry and Commerce of Central Switzerland) Innovation Award. The pioneering products, Geistlich Mucograft® and Geistlich Mucograft® Seal, were chosen as winners out of 23 projects.
  • A new clinical study has proven that ridge volume can be preserved if extraction alveoli are treated with Geistlich Bio-Oss® Collagen and Geistlich Bio-Gide®, regardless of the original thickness of the buccal bone plate.
  • Geistlich Pharma establishes its ninth affiliate, Geistlich Pharma Australia PTY Ltd. From 1 January 2015, Geistlich Pharma will be serving the Australian and New Zealand market directly from Sydney. The distributor up to now, Henry Schein, will remain the partner for general dental practitioners.
  • The EAO – the annual congress of the European Association for Osseointegration – is important for the industry. With around 3,000 participants, it is also well visited in Rome and receives a lot of recognition. Geistlich Pharma has a strong presence at the event.
  • Between 19 and 27 September, important congresses on regenerative dental medicine were held in the three metropolises of San Francisco, Shanghai and Rome. Geistlich managed the balancing act between three continents and between scientificity and practical relevance.
  • Between 19 and 27 September, important congresses on regenerative dental medicine were held in the three metropolises of San Francisco, Shanghai and Rome. Geistlich managed the balancing act between three continents and between scientificity and practical relevance.
  • A new Geistlich News is taking shape, featuring key topics, an array of guest contributions by esteemed experts and a revised layout. For our readers, this means more information – substantiated, practical and entertaining.
  • According to a court settlement of 12 May 2014, the South Korean company Osstem must refrain from any distribution of dental products under the name B-Oss and destroy all existing products bearing this name. The name and the packaging of this product were similar to that of the long-standing market leader Geistlich Bio-Oss®.
  • Geistlich Pharma wins the 2014 prize for innovation from the Chamber of Industry and Commerce of Central Switzerland (IHZ). The IHZ rated the products Geistlich Mucograft® and Geistlich Mucograft® Seal as an outstanding achievement.
PRESS CONTACT
Dr. Mirjam Kessler
Director Corporate Communications
PRESS CONTACT
Verena Vermeulen
Scientific Communication Manager